Wierzbicki, A S <br/><br/>
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.  [electronic resource] 

 -  International journal of clinical practice  Jun 2011 
 - 713-5 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1742-1241 
<br/><br/><label>Standard No.: </label>10.1111/j.1742-1241.2011.02683.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Biomarkers--metabolism<br/>Cannabinoid Receptor Modulators--antagonists & inhibitors<br/>Cholesterol--metabolism<br/>Fatty Liver--drug therapy<br/>Female<br/>Humans<br/>Hypercholesterolemia--drug therapy<br/>Insulin Resistance--physiology<br/>Male<br/>Middle Aged<br/>Non-alcoholic Fatty Liver Disease<br/>Obesity, Morbid--drug therapy<br/>Piperidines--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Retrospective Studies<br/>Rimonabant<br/>Safety-Based Drug Withdrawals<br/>Triglycerides--metabolism<br/>Weight Loss--drug effects